These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28626521)

  • 1. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.
    Puleo DE; Kucera K; Hammarén HM; Ungureanu D; Newton AS; Silvennoinen O; Jorgensen WL; Schlessinger J
    ACS Med Chem Lett; 2017 Jun; 8(6):618-621. PubMed ID: 28626521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
    Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.
    Henry SP; Liosi ME; Ippolito JA; Cutrona KJ; Krimmer SG; Newton AS; Schlessinger J; Jorgensen WL
    ACS Med Chem Lett; 2022 May; 13(5):819-826. PubMed ID: 35586418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
    Liosi ME; Ippolito JA; Henry SP; Krimmer SG; Newton AS; Cutrona KJ; Olivarez RA; Mohanty J; Schlessinger J; Jorgensen WL
    J Med Chem; 2022 Jun; 65(12):8380-8400. PubMed ID: 35653642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the structure and function of the pseudokinase domain in JAK2.
    Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
    Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
    Liosi ME; Krimmer SG; Newton AS; Dawson TK; Puleo DE; Cutrona KJ; Suzuki Y; Schlessinger J; Jorgensen WL
    J Med Chem; 2020 May; 63(10):5324-5340. PubMed ID: 32329617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
    Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
    PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
    Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
    Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.
    Sanz Sanz A; Niranjan Y; Hammarén H; Ungureanu D; Ruijtenbeek R; Touw IP; Silvennoinen O; Hilhorst R
    Biochim Biophys Acta; 2014 Oct; 1844(10):1835-41. PubMed ID: 25107665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
    Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
    Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
    Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.
    Newton AS; Liosi ME; Henry SP; Deiana L; Faver JC; Krimmer SG; Puleo DE; Schlessinger J; Jorgensen WL
    Tetrahedron Lett; 2021 Aug; 77():. PubMed ID: 34393283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.
    Saharinen P; Vihinen M; Silvennoinen O
    Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
    Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
    PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase.
    Hubbard SR
    Front Endocrinol (Lausanne); 2017; 8():361. PubMed ID: 29379470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
    Raivola J; Hammarén HM; Virtanen AT; Bulleeraz V; Ward AC; Silvennoinen O
    Front Oncol; 2018; 8():560. PubMed ID: 30560087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.